Current Research Trials
To make the process easier to navigate, the HCMA is happy to provide this new tool powered by our partner Antidote.
Not all clincial trials are listed here, but they can be accessed via this direct link to ClinicalTrials.gov (directly linked to all HCM trials), which lists all trials and is updated daily.
HCMA has short-listed those we feel you should be aware of on this page. The HCMA does not specifically endorse any trial on this list. We encourage each person to speak with their HCM care provider about which, if any, trial may be appropriate for them. We encourage you to read this link before participating in a clinical trial.
|Interventional||To evaluate the efficacay, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years||A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (PIONEER-HCM)|
|Observational||Identification of novel risk markers||HCMR – Novel Markers of Prognosis in Hypertrophic Cardiomyopathy|
|Observational||Determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy||
Exercise in Cardiovascular Conditions (LIVE-HCM)
|Interventional||If treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy||Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM (Vanish)|
|Observational||Identify genes that cause cardiomyopathy or that influence how people with cardiomyopathy do over time.||Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)|
|Observational||How helpful measuring cardiac biomarkers in Pediatric cardiomyopathy||Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)|
|Interventional||Develop a process to integrate WGS into clinical medicine and explore the impact of doing so.||A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare|
|Observational||10 year study to identify and trend care parameters, adverse events in the congenital muscle diseases using the Congenital Muscle Disease International Registry (CMDIR).||Congenital Muscle Disease Study of Patient and Family Reported Medical Information|